Experimental K9 pill tested for thyroid eye disease – but study stopped early
NCT ID NCT06467435
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an oral drug called K9 (kamuvudine-9) in people with thyroid eye disease, a condition that causes eye bulging and discomfort. The study planned to enroll up to 10 patients but was terminated after only 4 participants. The main goal was to check safety, not to prove the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Kamuvudine-9 (K9) tablets
- What this could lead to
- If it works, this could point toward a new oral treatment to control thyroid eye disease symptoms.
- What could go wrong
- This was a very small, early-phase safety study that was terminated early, so we have little data on effectiveness. The results may not apply to a larger population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Kentucky
Lexington, Kentucky, 40506, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody calm thyroid eye disease?
- Could a cholesterol drug shrink eye muscle swelling in thyroid eye disease?
- Can an experimental drug reduce eye bulging in thyroid eye disease?
- Can a new drug ease bulging eyes in thyroid disease?
- New drug IBI3031 enters first human trial for thyroid eye disease
- New hope for thyroid eye disease: drug shows promise in Steroid-Resistant patients